Endogenous tumour necrosis factor-alpha sensitise melanoma cells to glucosaminylmuramyl dipeptide

• Published in: FEBS letters 1998-04, Vol.426 (3), p.373-376
• Main Authors: Valyakina, Tatyana I, Komaleva, Ravilya L, Petrova, Elena E, Malakhov, Alexander A, Shamborant, Ol'ga G, Andronova, Tatyana M, Nesmeyanov, Vladimir A
• Format: Article
• Language: English
• Subjects: Acetylmuramyl-Alanyl-Isoglutamine - analogs & derivatives; Acetylmuramyl-Alanyl-Isoglutamine - pharmacology; Adjuvants, Immunologic - pharmacology; Animals; Antigens, Neoplasm - biosynthesis; Antigens, Neoplasm - drug effects; Cell-Free System - physiology; Culture Media, Conditioned - pharmacology; FCS, foetal calf serum; Flow Cytometry; GMDP, N-acetylglucosaminyl-β1–4-N-acetylmuramyl-alanyl-d-isoglutamine; Humans; mAb, monoclonal antibody; MDP, N-acetylmuramyl-alanyl-d-isoglutamine; Melanoma - immunology; Melanoma - metabolism; Melanoma-associated antigen; Mice; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Muramyl peptide; PBS, phosphate-buffered saline; TGF-β1β2β3, transforming growth factor-beta1,2,3; TNF-α, tumour necrosis factor-alpha; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha - physiology; Tumour necrosis factor
• ISSN: 0014-5793; 1873-3468
• DOI: 10.1016/S0014-5793(98)00376-7

Flow cytometry was used to demonstrate that cultured human melanoma BRO cells expressed membrane-bound tumour necrosis factor-alpha (TNF-α) and were able to release TNF-α upon treatment with glucosaminylmuramyl dipeptide (GMDP). The released TNF-α was shown to prime melanoma cells, previously unable to respond to GMDP by increasing expression of melanoma-associated antigens, making them sensitive to GMDP treatment.